HRGN (Harvard Apparatus Regenerative Technology) ROCE %: -991.63% (As of Mar. 2026)

What is Harvard Apparatus Regenerative Technology ROCE %?

Harvard Apparatus Regenerative Technology HRGN 34 ROCE % is -991.63% as of Mar. 2026. GuruFocus rates HRGN with a GF Score™ of 34/100 and a GF Value™ of $5.34 (Possible Value Trap). The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Harvard Apparatus Regenerative Technology's annualized ROCE % for the quarter that ended in Mar. 2026 was -991.63%.

Harvard Apparatus Regenerative Technology (OTCPK:HRGN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Harvard Apparatus Regenerative Technology ROCE % Related Terms

Harvard Apparatus Regenerative Technology ROCE % Historical Data

* Premium members only.

The historical data trend for Harvard Apparatus Regenerative Technology's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Harvard Apparatus Regenerative Technology ROCE % Chart

Harvard Apparatus Regenerative Technology Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

0.00

-665.75

-303.69

-300.66

Harvard Apparatus Regenerative Technology Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															-234.99	-465.77	-527.33	-479.49	-991.63

34GF Score

Harvard Apparatus Regenerative Technology Inc HRGN

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Harvard Apparatus Regenerative Technology ROCE % Calculation

Harvard Apparatus Regenerative Technology's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	-6.861	/	( ( (4.442 - 1.021)	+	(2.677 - 1.534) )	/ 2 )
	=	-6.861	/	( (3.421	+	1.143)	/ 2 )
	=	-6.861	/	2.282
	=	-300.66 %

Harvard Apparatus Regenerative Technology's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	-6.396	/	( ( (2.677 - 1.534)	+	(1.798 - 1.651) )	/ 2 )
	=	-6.396	/	( ( 1.143	+	0.147 )	/ 2 )
	=	-6.396	/	0.645
	=	-991.63 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -991.63% mean?

Harvard Apparatus Regenerative Technology (HRGN) has a ROCE % of -991.63% as of Mar. 2026.

Is Harvard Apparatus Regenerative Technology's ROCE % too high?

Harvard Apparatus Regenerative Technology's current ROCE % is -991.63%. Overall, Harvard Apparatus Regenerative Technology has a GF Score™ of 34/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Harvard Apparatus Regenerative Technology's ROCE % compare to DTEAF and WYGC?

Harvard Apparatus Regenerative Technology's ROCE % of -991.63% can be compared against companies in the Consumer Packaged Goods industry. The industry median ROCE % is 8.78. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Consumer Packaged Goods company?

The median ROCE % among Consumer Packaged Goods companies is 8.78, based on 1,938 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Consumer Packaged Goods industry, the median ROCE % is 8.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harvard Apparatus Regenerative Technology's current ROCE % is -991.63%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Harvard Apparatus Regenerative Technology stock overvalued right now?

Based on GuruFocus' analysis, Harvard Apparatus Regenerative Technology (HRGN) is currently considered Possible Value Trap. The stock's GF Value™ is $5.34, compared to a current price of $1.39 — trading 74% below its estimated fair value. The current ROCE % is -991.63%. Harvard Apparatus Regenerative Technology's overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Harvard Apparatus Regenerative Technology (HRGN), the current ROCE % is -991.63% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Harvard Apparatus Regenerative Technology (HRGN) Overvalued in 2026?

Based on GuruFocus' analysis, Harvard Apparatus Regenerative Technology stock appears to be undervalued. The current stock price of $1.39 is trading 74% below its estimated GF Value™ of $5.34. GuruFocus considers Harvard Apparatus Regenerative Technology to be Possible Value Trap.

Key valuation signals for HRGN:

ROCE %: -991.63%
GF Value™: $5.34 vs. price of $1.39 (74% below fair value)
GF Score™: 34/100 with 2 warning signs

No single metric tells the full story. See the HRGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Harvard Apparatus Regenerative Technology Business Description

Industry Consumer Defensive Consumer Packaged Goods

Comparable Companies DTEAF WYGC BFNH LIMX STCB FAMI COOT JVA CTGL NAII XSWX:NESN XPAR:BN BOG:NUTRESA TSE:2802 SHSE:603288 NSE:NESTLEIND KHC SHSE:600887 SZSE:300999 GIS

Address 84 October Hill Road, Suite 11, Holliston, MA, USA, 01746

Website https://www.biostage.com

Harvard Apparatus Regenerative Technology is a clinical-stage biotechnology company focused on the development of regenerative medicine treatments for disorders of the gastrointestinal system and other organs that result from cancer, trauma, or birth defects. Its technology is based on a proprietary cell-therapy platform that uses a patient's own stem cells to regenerate and restore function to damaged organs. The Company has two operating and reportable segments: Regenerative Biotech, focused on the development of regenerative medicine treatments with operations currently in the United States, and Consumer Health Products relating to consumer health products with operations currently in Asia.

34GF Score

Get the complete analysis for HRGN

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.39

Price

$5.34

GF Value

View HRGN Analysis

See ROCE % data for all stocks →